Roivant Sciences Ltd
NASDAQ:ROIV

Watchlist Manager
Roivant Sciences Ltd Logo
Roivant Sciences Ltd
NASDAQ:ROIV
Watchlist
Price: 23.13 USD -0.73% Market Closed
Market Cap: 16.1B USD

Operating Margin

-5 659.4%
Current
Declining
by 3 175.2%
vs 3-y average of -2 484.2%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-5 659.4%
=
Operating Income
$-1.2B
/
Revenue
$20.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-5 659.4%
=
Operating Income
$-1.2B
/
Revenue
$20.3m

Peer Comparison

Country Company Market Cap Operating
Margin
BM
Roivant Sciences Ltd
NASDAQ:ROIV
16B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
276.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
215.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
221.7B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...
No Stocks Found

Market Distribution

Lower than 99% of companies in Bermuda
Percentile
1st
Based on 195 companies
1st percentile
-5 659.4%
Low
-73 643.6% — 2.6%
Typical Range
2.6% — 19.1%
High
19.1% — 68.5%
Distribution Statistics
Bermuda
Min -73 643.6%
30th Percentile 2.6%
Median 6.8%
70th Percentile 19.1%
Max 68.5%

Roivant Sciences Ltd
Glance View

Market Cap
16.1B USD
Industry
Pharmaceuticals

Roivant Sciences Ltd. emerged as an intriguing figure in the pharmaceutical landscape, founded by the charismatic and driven Vivek Ramaswamy. The company operates like a strategic mosaic in the biotech industry, acquiring and developing promising drug candidates through a distinctive model that emphasizes speed and efficiency. At the heart of Roivant's strategy are its "Vants"—subsidiary companies that each focus on developing a specific type of therapeutic drug. This compartmentalized approach allows Roivant to cultivate multiple drug development streams simultaneously, mitigating risk while maximizing potential returns. By acquiring undervalued or overlooked drugs from larger pharmaceutical companies and advancing them through clinical trials, Roivant creates a robust pipeline of therapies ready to address unmet medical needs. Roivant generates revenue through the monetization of these therapies, either by bringing them to market directly or through strategic partnerships and licensing deals with larger pharmaceutical companies. By advancing drugs to critical points in clinical development, the company enhances their value significantly before either monetizing through commercialization or strategic exits like IPOs or partnerships. This business model creates a strong position in the drug development value chain, allowing Roivant to capture returns on its investments with focused precision. Additionally, Roivant brings an innovative twist to biotech investing by leveraging data analytics and technology to guide its decisions, aiming to streamline the traditionally costly and time-consuming drug development process. Beyond the financials, this approach paints Roivant as not just a player in biopharma but as an architect reshaping how medical innovations can reach patients more efficiently.

ROIV Intrinsic Value
3.83 USD
Overvaluation 83%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-5 659.4%
=
Operating Income
$-1.2B
/
Revenue
$20.3m
What is Roivant Sciences Ltd's current Operating Margin?

The current Operating Margin for Roivant Sciences Ltd is -5 659.4%, which is below its 3-year median of -2 484.2%.

How has Operating Margin changed over time?

Over the last 3 years, Roivant Sciences Ltd’s Operating Margin has decreased from -2 134.3% to -5 659.4%. During this period, it reached a low of -5 659.4% on Oct 30, 2025 and a high of -871.9% on Dec 31, 2023.

Back to Top